The 8 most recent market catalysts affecting $RGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Repligen, Raises Price Target to $225
UBS analyst Dan Leonard maintained a 'Buy' rating on Repligen and raised the price target from $195 to $225. This action signals increased confidence from a prominent financial ins…
Jul 30, 2026
Market Technicals
Bullish
Impact 55
Wells Fargo Maintains Overweight on Repligen, Raises Price Target to $185
Wells Fargo analyst Evan Stampler maintained an 'Overweight' rating on Repligen (RGEN) and raised the price target from $180 to $185. This action signals continued confidence in th…
Jul 29, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on Repligen, Raises Price Target to $175
JP Morgan analyst Casey Woodring has maintained an 'Overweight' rating on Repligen (RGEN) and raised the price target from $165 to $175. This action signals continued confidence fr…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
Repligen shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
This headline represents a major corporate catalyst for Repligen. Better-than-expected financial results indicate strong operational execution and demand for their products, while …
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
Repligen Q2 Adj. EPS $0.54 Beats $0.45 Estimate, Sales $204.128M Beat $201.483M Estimate
Repligen announced its Q2 earnings, reporting an adjusted EPS of $0.54, significantly beating the analyst consensus of $0.45. Sales also surpassed expectations, coming in at $204.1…
Jul 28, 2026
Corporate Catalyst
Neutral
Impact 75
Repligen Raises FY2026 Adj EPS Guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 Est; Raises FY2026 Sales Guidance from $803.000M-$833.000M to $813.000M-$835.000M vs $822.537M Est
Repligen filed an 8-K to announce an upward revision to its fiscal year 2026 adjusted EPS and sales guidance. This is significant because the new guidance ranges ($2.03-$2.09 for A…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 95
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
Repligen's acquisition of BioLife Solutions for $1.5 billion is a significant strategic move, positioning Repligen to capitalize on the rapidly expanding cell therapy market. The d…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 95
BioLife Solutions To Be Acquired By Repligen For $31 Per Share In Cash And RGEN Stock At EV Of ~$1.5B
Repligen (RGEN) is acquiring BioLife Solutions (BLFS) for an enterprise value of approximately $1.5 billion, with BioLife stockholders receiving $31.00 per share in cash and RGEN s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.